10X Genomics

TXG · NASDAQ

$71.46+$1.57 (+2.25%)TodayMarket closed · Oct 20, 7:46 PM ET

Prev close $69.89

TXG analyst rating

HoldConsensus of 15 analysts over the last 12 months. 40% rate it a buy.

Strong buy0
Buy6
Hold9
Underperform0
Sell0

12-month price target · 16 analysts

Average $60.62 (−15.2% downside)

Low: $40.40
Now: $71.46
High: $94.50

Upgrades and downgrades

The latest rating actions, newest first

TXG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Oct 13, 2026	Maintains	Hold	$47.00 → $70.00	61%
Morgan Stanley	Oct 13, 2026	Maintains	Equal-Weight	$40.00 → $70.00	48%
Canaccord Genuity	Oct 12, 2026	Maintains	Buy	$60.00 → $100.00	55%
Barclays	Oct 7, 2026	Maintains	Overweight	$52.00 → $110.00	54%
Leerink Partners	Sep 29, 2026	Maintains	Market Perform	$40.00 → $90.00	41%
Piper Sandler	Sep 28, 2026	Maintains	Neutral	$47.00 → $80.00	58%
Argus Research	Sep 28, 2026	Initiates	Buy	$110.00	65%
UBS	Sep 9, 2026	Maintains	Neutral	$20.00 → $68.00	59%
RBC Capital	Sep 1, 2026	Initiates	Sector Perform	$70.00	59%
Stephens & Co.	Aug 12, 2026	Maintains	Overweight	$50.00 → $65.00	51%

The case for and against

Updated Oct 21, 2026

Bull case

10x Genomics is supported by a compelling long-term growth profile because its integrated instruments, consumables, and software ecosystem is designed to capture recurring demand as customers expand multiomic and spatial biology workflows. The company’s Chromium, Visium, and Xenium platforms address complex biological analysis at scale, giving it a differentiated position in a market where technology depth and installed-base monetization can support durable revenue growth. In addition, its geographic reach across the United States, Europe, China, Asia-Pacific, and other regions broadens the addressable market and reduces reliance on any single end market.

Bear case

10x Genomics is facing a negative fundamental setup because market competition, technological obsolescence, regulation, dependence on key customers, and supply chain disruptions all threaten its ability to sustain growth and protect margins. Its recent production results were below estimates and consensus, with gold at 69.3 koz versus 78.8 koz estimated, copper at 13.9 Mlbs versus 15.3 Mlbs estimated, and silver at 520.2 koz versus 549.7 koz estimated, signaling execution risk and weaker-than-expected operating performance. Although 2026 guidance of 420–470 koz AuEq was reiterated, the reliance on planned lower grades and recoveries with improvement only stepping into H2/26 leaves limited near-term visibility and reinforces a cautious outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.